• Home
  • About Us
    • Company Overview
    • Management
    • Board of Directors
    • Advisors
    • Partnerships
    • Careers
  • Research & Development
    • Pipeline
    • Clinical Trials
    • Publications
  • Newsroom
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
      • Events
      • Corporate Presentation
    • Stock Data
      • Stock Quote & Chart
      • Analyst Coverage
    • Financials & Filings
      • SEC Filings
      • Quarterly Results
    • Governance
      • Documents & Charters
      • Committee Composition
    • Shareholder Resources
      • Email Alerts
      • FAQs
  • Contact

Reviva to Participate in the UBS Global Healthcare Conference

Oct 31, 2024 | Press Releases

CUPERTINO, Calif., Oct. 31, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024 | Press Releases

CUPERTINO, Calif., Oct. 08, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024 | Press Releases

CUPERTINO, Calif., Oct. 02, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...

Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference

Sep 26, 2024 | Press Releases

CUPERTINO, Calif., Sept. 26, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Sep 9, 2024 | Press Releases

– Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of schizophrenia – – Additional vocal biomarker data from ongoing open label extension...

Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024 | Press Releases

CUPERTINO, Calif., Sept. 04, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
« Older Entries
Next Entries »

Recent Posts

  • Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
  • Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
  • Reviva to Participate in Upcoming Investor Conferences in May 2025
  • Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights
  • Reviva to Participate in the A.G.P. Healthcare Company Showcase

Recent Comments

No comments to show.

CONTACT

Reviva Pharmaceuticals Holdings, Inc.
10080 N Wolfe Road, Suite SW3-200
Cupertino, CA 95014

Phone: +1.408.501.8881
Email: [email protected]

  • Follow
  • Follow
Sign Up for Email Alerts

SITE LINKS

  • Home
  • Investors
  • Newsroom
  • Privacy Policy
  • Contact
  • Sitemap

Our COMPANY

  • About us
  • Management
  • Board of Directors
  • Advisors
  • Partnerships
  • Careers

RESEARCH & DEVELOPMENT

  • Pipeline
  • Clinical Trials
  • Publications
Reviva Pharmaceuticals Holdings, Inc. ©2025.   All Rights Reserved.
We value your privacy. We use cookies and other technologies to keep the site reliable and secure, measure site performance, tailor your experience, and deliver up to date stock data and financial information. By using our site, you agree to our use of cookies as described in our Privacy Policy.AcceptPrivacy policy